Immediate Answer: The U.S. Food and Drug Administration has granted full approval to Simtriyo (centanafadine), developed by Otsuka Pharmaceutical, as the first-ever triple reuptake inhibitor for Attention Deficit Hyperactivity Disorder. Acting on norepinephrine, dopamine, and serotonin, Simtriyo provides a novel pharmacological option for adults and pediatric patients aged 6 and older, offering renewed hope for families seeking effective management strategies. What Happened:
